Stock Performance (Historical, facts from public market data as of mid-2026):
Interpretation: The stock has shown strong long-term gains likely driven by clinical progress and market interest in ophthalmology biotech, but short-term fluctuations reflect typical pre-revenue biotech volatility and news sensitivity.
Uncertainties: Historical returns do not predict future performance; biotech stocks can experience sharp declines on trial setbacks or dilution.
Key Financials (facts from company reports and filings, FY2025 and recent quarters):
| Metric | Value/Details |
|---|---|
| Revenue (TTM) | $0 (pre-revenue clinical-stage company) |
| Net Loss (FY2025) | $43.4 million (improved from $69.2 million in FY2024) |
| EPS (TTM) | Approximately -$0.78 to -$2.18 (negative, as expected) |
| Cash & Marketable Securities | ~$97–118 million (post $50M private placement in late 2025) |
| Employees | 20 |
| Cash Runway | Expected into 2027 |
| Market Cap | Approximately $110–130 million range (varies with share price) |
Balance sheet shows no significant debt reported in available data; focus remains on R&D spending.
Limitation/Assumption: Financial data derived from public earnings releases and aggregators (e.g., Yahoo Finance, company IR) as of early-mid 2026; exact quarterly details may vary; no revenue or profitability forecasts provided by company beyond runway statements. Full audited statements available in SEC filings.
Links for more information:
Consensus (facts from analyst coverage aggregators as of mid-2026):
Interpretation: Analysts appear optimistic about TH103's potential differentiation in the anti-VEGF space and the company's progress toward Phase 3, reflecting confidence in the scientific foundation (led by VEGF pioneer Dr. Napoleone Ferrara).
Uncertainties: Analyst ratings can change rapidly with new data; targets are estimates, not guarantees; coverage may be limited due to small market cap.
Limitation: Ratings aggregated from sources like MarketBeat, TipRanks, Yahoo; exact number of analysts and recency varies; always verify latest reports.
Links for more information:
Facts: Kalaris is pre-commercial with no approved products or revenue-generating customers. The target patient population consists of individuals with prevalent retinal diseases (e.g., wet AMD, diabetic macular edema, retinal vein occlusion) who currently rely on frequent anti-VEGF injections.
Interpretation: Potential future customers would be ophthalmology clinics, retina specialists, and patients seeking longer-acting therapies to reduce treatment burden.
Uncertainties: Commercial success depends on regulatory approval, reimbursement, and real-world adoption; no current sales or partnerships disclosed for revenue.
Key Competitors in Wet AMD / Retinal Anti-VEGF Space (facts from market reports):
| Company | Key Product/Asset | Notes |
|---|---|---|
| Regeneron Pharmaceuticals | Eylea (aflibercept), Eylea HD | Market leader in anti-VEGF injections |
| Roche / Genentech (with Bayer, Novartis) | Vabysmo (faricimab), Lucentis (ranibizumab) | Dual-action and established therapies |
| Kodiak Sciences | KSI-501 / KSI-301 | Longer-acting candidates in development |
| REGENXBIO / AbbVie | RGX-314 (gene therapy) | Alternative delivery approaches |
| Apellis Pharmaceuticals | Syfovre (complement inhibitor, dry AMD focus) | Adjacent retinal space |
| Others (e.g., Outlook Therapeutics, EyePoint) | Biosimilars / sustained-release | Emerging options |
Kalaris positions TH103 as potentially differentiated via enhanced potency, intraocular retention, and durability signals from preclinical and early clinical data.
Interpretation: Competition is intense in the established anti-VEGF market; success hinges on demonstrating superior durability or efficacy in later trials.
Uncertainties: Pipeline competitors may advance faster or achieve better outcomes; biosimilars could pressure pricing.
Limitation: Competitor list focused on wet AMD anti-VEGF; broader ophthalmology landscape includes many players; data from market analyses (e.g., DelveInsight) as of 2025–2026.
Links for more information: